Guanosine

Guanosine

SCHEMBL4874332

Nc1nc2c(ncn2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1.Nc1ncnc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 5/20 0.63
DNMT3B Q9UBC3 3/20 0.63
FPR2 P25090 2/20 0.63
DPP4 P27487 1/20 0.63
MEN1 O00255 1/20 0.63
SLC28A1 O00337 1/20 0.63
MAP3K7 O43318 1/20 0.63
SLC28A2 O43868 1/20 0.63
GAPDH P04406 1/20 0.63
ADORA3 P0DMS8 1/20 0.63
MAPK1 P28482 1/20 0.63
ADORA2A P29274 1/20 0.63
ADORA2B P29275 1/20 0.63
ADORA1 P30542 1/20 0.63
STAT6 P42226 1/20 0.63
PI4KA P42356 1/20 0.63
KMT2A Q03164 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
PI4K2B Q8TCG2 1/20 0.63
DOT1L Q8TEK3 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Deoxyguanosine SCHEMBL27992930 1.00 DNMT1 (0.63) DNMT1DNMT3BFPR2DPP4MEN1
Guanosine SCHEMBL27992737 1.00 DNMT1 (0.63) DNMT1DNMT3BFPR2DPP4MEN1
Guanosine SCHEMBL5027190 0.93 HPGD (0.63) SMN1; SMN2HPGDP2RY2P2RY4P2RY6
Guanosine SCHEMBL8524537 0.93 HPGD (0.63) SMN1; SMN2HPGDP2RY2P2RY4P2RY6
Deoxyguanosine SCHEMBL6372750 0.93 PNP (0.61) DNMT1DNMT3BFPR2SMN1; SMN2STING1
Guanosine SCHEMBL6856847 0.92 ADORA3 (0.75) DPP4MEN1SLC28A1MAP3K7SLC28A2
Guanosine SCHEMBL7722707 0.92 ADORA3 (0.75) DPP4MEN1SLC28A1MAP3K7SLC28A2
Guanosine SCHEMBL531212 0.92 ADORA3 (0.75) DPP4MEN1SLC28A1MAP3K7SLC28A2
Adenosine SCHEMBL5150670 0.89 ADORA3 (0.80) DNMT1DNMT3BFPR2DPP4MEN1
Adenosine SCHEMBL3207685 0.89 P2RY2 (0.70) SMN1; SMN2P2RY2P2RY4P2RY6DTYMK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080145372-A1 Bioreductively-Activated Prodrugs ANGIOGENE, PHARMACEUTICALS LIMITED (GB) 2008-06-19 US claimed
EP-1799698-A1 BIOREDUCTIVELY-ACTIVATED PRODRUGS Angiogene Pharmaceuticals Limited (GB) 2007-06-27 EP claimed
WO-2006032921-A1 BIOREDUCTIVELY-ACTIVATED PRODRUGS ANGIOGENE PHARMACEUTICALS LIMITED (GB) 2006-03-30 WO claimed
US-20080145372-A1 Bioreductively-Activated Prodrugs ANGIOGENE, PHARMACEUTICALS LIMITED (GB) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080145372-A1 Bioreductively-Activated Prodrugs NME2, PNP, NUDT1 DNMT1 3747/4885DNMT3B 3356/4885FPR2 2525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.